Search results
Showing 376 to 390 of 600 results for diabetes
This guideline covers diagnosing and treating fertility problems. It aims to reduce variation in practice and improve the way fertility problems are investigated and managed.
This quality standard covers improving nutrition for pregnant women, and babies and children under 5 and their mothers and carers. It focuses on low-income and disadvantaged families. It describes high-quality care in priority areas for improvement.
View quality statements for QS98Show all sections
Sections for QS98
- Quality statements
- Quality statement 1: Healthy eating in pregnancy
- Quality statement 2: Structured weight-loss programme
- Quality statement 3: Healthy Start scheme
- Quality statement 4: Breastfeeding
- Quality statement 5: Advice on introducing solid food
- Quality statement 6: Advice on Healthy Start prepaid cards
- Update information
Coeliac disease: recognition, assessment and management (NG20)
This guideline covers the recognition, assessment and management of coeliac disease in children, young people and adults.
Lumella point-of-care test for assessing pre-eclampsia risk (MIB287)
NICE has developed a medtech innovation briefing (MIB) on Lumella point-of-care test for assessing pre-eclampsia risk .
Tocilizumab for the treatment of systemic juvenile idiopathic arthritis (TA238)
Evidence-based recommendations on tocilizumab (RoActemra), for treating systemic juvenile idiopathic arthritis in people aged 2 and over.
Ticagrelor for the treatment of acute coronary syndromes (TA236)
Evidence-based recommendations on ticagrelor (Brilique) for treating acute coronary syndromes in adults.
NICE visualisation of treatment options incorporating technology appraisals: interim process guide
YOURmeds for medication support in long-term conditions (MIB289)
NICE has developed a medtech innovation briefing (MIB) on YOURmeds for medication support in long-term conditions .
This quality standard covers identifying and managing atrial fibrillation (including paroxysmal, persistent and permanent atrial fibrillation, and atrial flutter) in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS93Show all sections
Sections for QS93
- List of quality statements
- Quality statement 1: Anticoagulation to reduce stroke risk
- Quality statement 2: Use of aspirin
- Quality statement 3: Discussing options for anticoagulation
- Quality statement 4: Anticoagulation control
- Quality statement 5: Referral for specialised management
- Quality statement 6 (developmental): Self-monitoring of anticoagulation
- Update information
Low-intensity pulsed ultrasound to promote healing of delayed-union and non-union fractures (IPG623)
Evidence-based recommendations on low-intensity pulsed ultrasound to promote healing of delayed-union and non-union fractures in adults. This involves using an ultrasound probe on the skin at the site of the fracture.
View recommendations for IPG623Show all sections
Antenatal and postnatal mental health: clinical management and service guidance (CG192)
This guideline covers recognising, assessing and treating mental health problems in women who are planning to have a baby, are pregnant, or have had a baby or been pregnant in the past year. It covers depression, anxiety disorders, eating disorders, drug- and alcohol-use disorders and severe mental illness (such as psychosis, bipolar disorder and schizophrenia). It promotes early detection and good management of mental health problems to improve women’s quality of life during pregnancy and in the year after giving birth.
Dupilumab for treating severe asthma with type 2 inflammation (TA751)
Evidence-based recommendations on dupilumab (Dupixent) for treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over.
This guideline covers how to communicate the risks and benefits of natural sunlight exposure (specifically, the ultraviolet rays UVA and UVB) to help people understand why they may need to modify their behaviour to reduce their risk of skin cancer and vitamin D deficiency.
This guideline covers changing health-damaging behaviours among people aged 16 and over using interventions such as goals and planning, feedback and monitoring, and social support. It aims to help tackle a range of behaviours including alcohol misuse, poor eating patterns, lack of physical activity, unsafe sexual behaviour and smoking.
Summary of the evidence on omega-3 fatty acid medicines for treating schizophrenia to inform local NHS planning and decision-making